Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Atopic Dermatitis
Recon: FDA clears Pfizer recall for 12-15 year olds; Teva found responsible in opioid lawsuit in…
Posted on January 03, 2022 | Through Joanne S. Eglovich
Welcome to Regulatory Reconnaissance, your daily briefing on regulatory news and intelligence.
Focus: United States…
How To Do Microdermabrasion At Home – Expert Advice
Some skin care is best left to the pros. Certain types of peels. lasers and deeper levels of light therapy should be done by a knowledgeable and certified expert. However, at-home microdermabrasion is a treatment that, with proper…
Stock traders buy large volume of call options on Forte Biosciences (NASDAQ: FBRX)
Forte Biosciences, Inc. (NASDAQ: FBRX) was the target of unusual options trading activity on Wednesday. Stock traders acquired 30,205 call options on the company. This represents an increase of 1,663% over the average volume of 1,713…
BioMe Inc. and Yonsei Medical Center sign technology
SEOUL, South Korea, December 29, 2021 (GLOBE NEWSWIRE) - The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various incurable diseases. However, recent reports of…
Does atopic dermatitis have an increased risk of acquiring COVID-19?
Based on the best available evidence, patients with atopic dermatitis (AD) do not appear to face an increased risk of contracting COVID-19 or being hospitalized because of the virus.
“This is an area that will continue to…
4 benefits of probiotics beyond gut health
When you think of “probiotics,” what's the first thing that comes to your mind? While the words “gut health” immediately appeared in your brain, you're not the only one associating good bacteria with…
Breakthroughs and disappointments of 2021
Major breakthroughs1. FDA approval of the first topical Janus kinase (JAK) inhibitor to treat atopic dermatitis (AD). “While there were new drug and device approvals, none were truly a 'breakthrough' except for ruxolitinib, a topical JAK…
Allakos announces first phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS…
REDWOOD CITY, Calif., December 21, 2021 (GLOBE NEWSWIRE) - Allakos, Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophils and mast cell disease,…
Global TIGIT Inhibitor Industry – With Acrus Biosciences, Astellas Pharma and AstraZeneca,…
DUBLIN, 20 December 2021 / PRNewswire / - "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been added to ResearchAndMarkets.com offer.Research and Markets logoThe T cell immunoreceptor with Ig and…
Winter Proofing Skin Care: Give Your Skin The Care It Needs When The Mercury Goes Down
Winter is an exciting time, but with all the fun come skin problems - dryness,…